We are live on ! Find out more
VRAX icon

Virax Biolabs
VRAX

7 hedge funds and large institutions have $81.8K invested in Virax Biolabs in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

553% more capital invested

Capital invested by funds: $12.5K → $81.8K (+$69.3K)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

133% more funds holding

Funds holding: 3 → 7 (+4)

2.26% more ownership

Funds ownership: 0.74% → 3% (+2.3%)

Holders
7
Holders Change
+4
Holders Change %
+133.33%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$27.8K
2
HF
HRT Financial
New York
+$25.4K
3
Renaissance Technologies
Renaissance Technologies
New York
+$10.9K
4
UBS Group
UBS Group
Switzerland
+$3K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$297

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$10.6K

VRAX Hedge Fund Activity: Q2 2024 in Review

7 of the 6,938 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q2 2024, worth a combined $81.8K — up 553% from $12.5K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new VRAX positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $27.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $10.6K sold.

  • 7 institutional investors held Virax Biolabs (VRAX) as of Q2 2024, up from 3 in Q1 2024.
  • Funds reported $81.8K of Virax Biolabs stock for Q2 2024, up 553% quarter-over-quarter.
  • 5 funds opened new Virax Biolabs positions in Q2 2024 and 1 closed out, a net change of +4 holders.
  • The largest Virax Biolabs buyer in Q2 2024 was Virtu Financial, an estimated $27.8K added.
  • The largest Virax Biolabs seller in Q2 2024 was Citadel Advisors, an estimated $10.6K sold.

Based on aggregated 13F filings for Q2 2024.